Mizuho Downgrades Apogee Therapeutics to Hold
Mizuho lowers Apogee Therapeutics to a hold rating with a $135 price target, a 1.75% upside from the current price.
Key Points
- Mizuho downgraded Apogee Therapeutics to a hold rating with a $135 price target on June 24, 2026.
- Mizuho's $135 price target implies 1.75% upside from Apogee Therapeutics, Inc.'s ($APGE) current $132.68 share price.
- Shares of APGE traded near $132.88 on Wednesday, with a market cap of $9.99 billion and a 52-week high of $133.
- Several other firms, including Deutsche Bank and Citigroup, also downgraded Apogee to hold recently.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Mizuho has downgraded its rating on Apogee Therapeutics, Inc. (NasdaqGM: APGE) to hold, setting a price target of $135. This change was reported on June 24, 2026, reflecting a more cautious stance on the stock. Apogee shares traded around $132.88 on Wednesday.
Mizuho vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Apogee Therapeutics, Inc. Stock Down 1.7%
Shares of Apogee Therapeutics, Inc. traded near $132.88 on Wednesday. The company, with a market cap of approximately $9.99 billion, operates in the biotechnology industry. Its stock has experienced a 52-week range from a low of $34.34 to a high of $133. The forward P/E ratio is not meaningful as the company is not currently profitable, with a beta of 0.619. Apogee has a strong liquidity position, reflected in its current ratio of 32.59 and quick ratio of 32.39.
$APGE price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Analysts Set New Price Targets
On June 24, 2026, Mizuho downgraded Apogee Therapeutics to a hold rating, setting a price target of $135. Similarly, Deutsche Bank and Citigroup also downgraded the stock to hold with the same price target on June 23, 2026. RBC Capital maintained its hold rating with a $135 target. The consensus among analysts is a strong buy, with an average target price of $119.5 across 16 opinions.
Other Institutional Activity in Apogee Therapeutics
T. Rowe Price Investment Management, Inc. significantly increased its stake in Apogee Therapeutics, adding 7,568,528 shares to hold a total of 10,300,984 shares valued at approximately $867.03 million. FMR LLC also raised its holdings by 1,037,253 shares, reaching a total of 9,262,291 shares worth about $779.61 million. Meanwhile, Wellington Management Group LLP reduced its position by 370,882 shares, ending with 4,375,703 shares valued at $368.30 million.
Insider Buying and Selling at Apogee Therapeutics, Inc.
On June 10, 2026, CEO Dr. Michael Thomas Henderson sold 20,000 shares at an average price of $83.38 as part of a planned transaction. Earlier, on June 9, 2026, several insiders, including Mark McKenna and William Jones Jr., each acquired 7,657 shares, with the transactions not being part of any pre-arranged plan.
About Apogee Therapeutics
Apogee Therapeutics, Inc., based in Waltham, Massachusetts, is a biotechnology company focused on developing novel biologics for inflammatory and immunology conditions. Led by CEO Dr. Michael Thomas Henderson, the company is advancing treatments for atopic dermatitis, asthma, and other diseases, with several candidates in various stages of clinical trials. Founded in 2022, Apogee employs 261 people.
Bottom Line
Mizuho's downgrade of Apogee Therapeutics to hold reflects a shift in sentiment among analysts, with several firms adjusting their outlooks. The stock remains a point of interest due to its innovative pipeline and recent market performance. Investors will watch upcoming earnings on August 10, 2026, for further insights.
Get Apogee Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $APGE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.